Log In Sign up
The largest database of trusted experimental protocols

96 well clear bottom black microplate

Manufactured by Corning
Visit Supplier
Sourced in United States

The 96-Well Clear Bottom Black Microplate is a laboratory equipment designed for a variety of cell-based assays. It features a clear bottom and a black opaque wall, which allows for optimal optical clarity and reduced well-to-well crosstalk. The microplate is made of high-quality materials and is suitable for a range of applications that require precise, reproducible results.

Automatically generated - may contain errors

Lab products found in correlation

Normocin, by InvivoGen (2 mentions) Quanti luc, by InvivoGen (2 mentions) Penicillin streptomycin glutamine (psg), by Thermo Fisher Scientific (2 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (2 mentions) Zeocin, by InvivoGen (2 mentions) Celltiter blue cell viability assay, by Promega (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Infinite m200 pro microplate reader, by Tecan (1 mentions) Prism 6, by GraphPad (1 mentions) Infinite m200 pro multimode microplate reader, by Tecan (1 mentions) Celltiter glo luminescent cell viability assay, by Promega (1 mentions) Prism 9, by GraphPad (1 mentions) Celltiter glo, by Promega (1 mentions) Ht29 lucia ahr cells, by InvivoGen (1 mentions)

Close spelling variants of this product

96-well microplates (290 citations) 96 wells (10 citations)

5 protocols using 96 well clear bottom black microplate

1

High-Throughput Drug Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
A panel of 120 drugs, either FDA-approved or in clinical trial was obtained from Selleckchem, (Houston, TX). All drugs in this study were dissolved in 100% dimethylsulfoxide (DMSO, Sigma-Aldrich) and stored as 10 mM stock. For the preliminary drug screen, cells were plated with culture media in 96-well clear bottom black microplates (Corning Costar) at a density of 5 × 103 cells per well and cultured overnight at 37° C with 5% CO2. The next day, cells were treated with either vehicle (DMSO) or one three drug concentrations (0.1 μM, 1 μM, and 10 μM in 0.5% DMSO) in triplicate for 72 h. The drugs were given to the cells at a final concentration of 0.5% DMSO. Cell viability was measured using the CellTiter-Blue Cell Viability Assay (Promega) according to the manufacturer’s instructions and an Infinite M200 Pro microplate reader (Tecan). The potency (IC50) of each drug was calculated by nonlinear least-squares curve-fitting using Prism 6 (GraphPad). Selected drugs were further assessed using a 13-point concentration range with 2-fold dilutions in triplicate to confirm key findings from the drug screen.
Zhang L., Nesvick C.L., Day C.A., Choi J., Lu V.M., Peterson T., Power E.A., Anderson J.B., Hamdan F.H., Decker P.A., Simons R., Welby J.P., Siada R., Ge J., Kaptzan T., Johnsen S.A., Hinchcliffe E.H, & Daniels D.J. (2022). STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma. Neuro-Oncology, 24(10), 1700-1711.
+ Open protocol
+ Expand
2

Quantifying Cell Viability Responses

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells in single-cell suspension were plated with culture medium in 96-well clear-bottom black microplates (Cat #3917; Corning Costar, Corning, NY, USA) at a density of 2500 cells per well for adult GBM cell lines (GBM6, GBM 10, GBM14, GBM 39, GBM43, and GBM 108) or 5000 cells per well for DMG cell lines (SU-DIPG XIII-P [47 (link)], SU-DIPG XVII [48 (link)], SF8628, SF8628-B23 (H3F3A K27M knockout of SF8628), and PED17) and cultured overnight at 37 °C with 5% CO2. The next day, cells were treated in triplicate with either vehicle (ddH2O or PBS) or serial dilutions of IL-13 (to final concentrations of 100, 50, 20, 10, 5, 1, and 0.5 ng/mL) or GB-13 (to final concentrations of 320, 100, 32, 10, 3.2, 1, 0.32, 0.1, 0.032, 0.01, 0.0032, and 0.001 ng/mL). Cells were incubated for 72 h and then assayed with CellTiter-Glo Luminescent Cell Viability Assay (Cat #G7570; Promega, Madison, WI, USA) according to the manufacturer’s recommendations. Luminescence was measured using an Infinite M200 PRO multimode microplate reader (Tecan Group, Männedorf, Switzerland), normalized to control wells (ddH2O or PBS only), and relative luminescence treatment was plotted as a function of drug concentration. The potency (50% inhibitory concentration, IC50) of each treatment was calculated by non-linear least-squares curve fitting using Prism 9 (GraphPad, San Diego, CA, USA).
Rechberger J.S., Porath K.A., Zhang L., Nesvick C.L., Schrecengost R.S., Sarkaria J.N, & Daniels D.J. (2022). IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics, 14(5), 922.
+ Open protocol
+ Expand
3

Evaluating Dabrafenib-JNK-IN-8 Combination

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were plated in a 96-well clear bottom black microplate (Corning) with complete culture medium for 18 h. Cells were treated with increasing concentrations of dabrafenib in the presence or absence of JNK-IN-8 for 72 h. Cell viability was assessed with Cell Titer Glo (Promega) according to the manufacturer’s instructions. Sigmoid curve fitting was performed with a four-parameter logistic equation implemented with Prism (GraphPad Inc.).
Du L., Anderson A., Nguyen K., Ojeda S.S., Ortiz-Rivera I., Nguyen T.N., Zhang T., Kaoud T.S., Gray N.S., Dalby K.N, & Tsai K.Y. (2019). JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS chemical biology, 14(7), 1426-1435.
+ Open protocol
+ Expand
4

AhR Activation Assay with HT29-Lucia Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HT29-Lucia™ AhR cells were purchased from InvivoGen (ht2l-ahr). Cells were cultured in DMEM (Gibco) supplemented with 10% FBS, 1x Penicillin-Streptomycin-Glutamine (Gibco), 100 ug/mL Normocin (InvivoGen), and 100 ug/mL selective antibiotic Zeocin (InvivoGen). Briefly, 20 μL of sample was incubated with ~50,000 HT29-Lucia™ AhR Cells for 24 h. Following incubation, 20 uL of supernatant was transferred into a 96-Well Clear Bottom Black Microplate (Corning) and 50uL QUANTI-Luc™ (InvivoGen) was added. Samples were immediately read for luminescence via a SpectraMax® i3x using SoftMax Pro 3.0.7 Software under the following settings: read type endpoint at all wavelengths, integration time 100ms, read height 2mm.
Pandey S.P., Bender M.J., McPherson A.C., Phelps C.M., Sanchez L.M., Rana M., Hedden L., Sangani K.A., Chen L., Shapira J.H., Siller M., Goel C., Verdú E.F., Jabri B., Chang A., Chandran U.R., Mullett S.J., Wendell S.G., Singhi A.D., Tilstra J.S., Pierre J.F., Arteel G.E., Hinterleitner R, & Meisel M. (2022). Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell host & microbe, 30(7), 1003-1019.e10.
+ Open protocol
+ Expand
5

Quantifying AhR Activation in HT29-Lucia Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Luciferase-expressing HT29-Lucia™ AhR reporter cells under the control of Cyp1a1 gene promoter (referred to as “AhR reporter cells”) were purchased from InvivoGen (ht2l-ahr). Cells were cultured in DMEM (Gibco) supplemented with 10% FBS, 1 x Penicillin-Streptomycin-Glutamine (Gibco), 100 µg/mL Normocin (InvivoGen), and 100 µg/mL selective antibiotic Zeocin (InvivoGen). Briefly, 20 µL of sample was incubated with approximately 50,000 AhR reporter cells for 24 h. Following incubation, 20 µL of supernatant was transferred into a 96-Well Clear Bottom Black Microplate (Corning) and 50 µL QUANTI-Luc™ (InvivoGen) was added. Samples were immediately read for luminescence via a SpectraMax® i3x using SoftMax Pro 3.0.7 Software under the following settings: read type endpoint at all wavelengths, integration time 100 ms, read height 2 mm.
Negrutskii B.S, & Deutscher M.P. (1992). A sequestered pool of aminoacyl-tRNA in mammalian cells.. Proceedings of the National Academy of Sciences of the United States of America, 89(8), 3601-3604.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!